Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## **144: Filer Information**

Filer CIK0001778307Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE INFORMATIONSubmission Contact InformationIs the second second

Name Phone E-Mail Address

## **144: Issuer Information**

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Akero Therapeutics, Inc. 001-38944 601 Gateway Blvd. Suite 350 South San Francisco CALIFORNIA 94080 650-487-6488 Andrew Cheng

President, CEO and Director

### **144: Securities Information**

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017	150000	5326500	56297528	03/04/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

# **144: Securities To Be Sold**

Title of the Date you

Nature of

Name of

Is Date

Amount of

Date of

Nature of

Class	Acquired	Acquisition Transaction	Person from Whom Acquired			Payment	Payment *
Common Stock	03/04/2024 <mark>S</mark> E	tock Option Exercise	Issuer		150000	03/04/2024 Ca	sh

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Nothing to Report

#### 144: Remarks and Signature

RemarksThe shares covered by this filing are stock options that will be exercised on<br/>03/04/24 or within three months from the date of this filing.Date of Notice03/04/2024Date of Plan Adoption or Giving of<br/>Instruction, If Relying on Rule 10b5-105/24/2023ATTENTION:05/24/2023

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Andrew Cheng *ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)*